AI Article Synopsis
- NDRG1 is a metastasis suppressor that inhibits various cancer signaling pathways, particularly those induced by the ErbB family of receptors.
- It works by preventing the formation of key receptor dimers (EGFR/HER2 and HER2/HER3) and promoting the degradation of the EGFR.
- Gaining insights into the relationship between NDRG1, iron, and ErbB signaling could lead to new and effective cancer treatment options.
Article Abstract
The iron-regulated metastasis suppressor N-myc downstream-regulated gene 1 (NDRG1) has been shown to inhibit numerous oncogenic signaling pathways in cancer cells. Recent findings have demonstrated that NDRG1 inhibits the ErbB family of receptors, which function as key inducers of carcinogenesis. NDRG1 attenuates ErbB signaling by inhibiting formation of epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) and HER2/HER3 heterodimers and by down-regulating EGFR via a mechanism involving its degradation. Understanding the complex interplay between NDRG1, iron, and ErbB signaling is vital for identifying novel, more effective targets for cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546018 | PMC |
| http://dx.doi.org/10.1074/jbc.R117.776393 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
BMP4 regulates differentiation of nestin-positive stem cells into melanocytes.
Cell Mol Life Sci
January 2025
Department of Anesthesiology, Shenzhen Children's Hospital, Yitian Road 7019, Shenzhen, 518000, China.
Hair follicle (HF) development and pigmentation are complex processes governed by various signaling pathways, such as TGF-β and FGF signaling pathways. Nestin + (neural crest like) stem cells are also expressed in HF stem cells, particularly in the bulge and dermal papilla region. However, the specific role and differentiation potential of these Nestin-positive cells within the HF remain unclear, especially regarding their contribution to melanocyte formation and hair pigmentation.
View Article and Find Full Text PDFFunctional analysis of the PIP5K1A gene in Liaoning Cashmere goats: an investigation based on bioinformatics, tissue localization, and biological functions.
Cell Mol Biol (Noisy-le-grand)
January 2025
College of Life Sciences, Liaoning Normal University, Dalian 116000, Liaoning Province, China.
Liaoning cashmere goat is an outstanding breed in China primarily for cashmere production, with strict controls against genetic outflow. Melatonin(MT) is a key factor affecting cashmere growth, and preliminary transcriptome sequencing indicated that melatonin upregulates the expression of the PIP5K1A gene in skin fibroblasts. To predict the physicochemical properties of PIP5K1A in Liaoning cashmere goats, ascertain the tissue localization of PIP5K1A in their skin, and explore the role and mechanism of PIP5K1A in the proliferation of skin fibroblasts.
View Article and Find Full Text PDFAtropine plus omeprazole for acute gastritis: Efficacy and safety analysis.
Pak J Pharm Sci
January 2025
Jian'ou Municipal Hospital, Nanping, Fujian, China.
This article primarily discusses the efficacy and safety of atropine (ATR) plus omeprazole (OME) for the treatment of acute gastritis (AG). From May 2022 to May 2024, 95 AG patients were selected, including 50 cases treated with ATR+OME (observation group) and 45 cases with anisodamine (ADM) plus OME (control group). Comparative analyses of the following dimensions were then carried out: Clinical efficacy, safety (xerostomia, palpitations and headaches), symptom remission time (stomach pain, abdominal distension and nausea and vomiting), serum inflammatory factors (tumor necrosis factor [TNF]-α, interleukin [IL]-6 and interferon [IFN]-β) and plasma gastrointestinal hormones (epidermal growth factor [EGF], gastrin [GAS] and somatostatin [SS]).
View Article and Find Full Text PDF[A Review of progresses in research on delayed resistance to EGFR-TKI by Traditional Chinese medicine via inhibiting cancer stem cells properties].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
January 2025
Department of Integrated Traditional Chinese and Western Medicine, Shandong First Medical University Affiliated Cancer Hospital, Jinan 250117, China. *Corresponding author, E-mail:
It has been popular and challenging to undertake researches on the delay of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). As key cells for tumor initiation, cancer stem cells (CSC) play an important role in the process of resistance to EGFR-TKI. Although preliminary studies found that traditional Chinese medicine (TCM) could inhibit CSC properties and delay EGFR-TKI resistance, the specific molecular mechanism remains unclear.
View Article and Find Full Text PDFQuality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.
Eur J Cancer
December 2024
International Breast Cancer Center, Quirónsalud Group, Barcelona, Spain; IOB Madrid, Hospital Beata Maria Ana, Madrid, Spain; Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas & Co, Jersey City (New Jersey, USA), Sao Paulo, Brazil; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
Objective: DESTINY-Breast03, a randomised, phase 3 trial, evaluated trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor (HER2)-positive unresectable and/or metastatic breast cancer who progressed on or after treatment with trastuzumab and a taxane. At the current data cut off overall survival analysis, T-DXd demonstrated a substantial improvement in overall survival over T-DM1. This secondary analysis use of DESTINY-Breast03 aimed to further evaluate the treatment differences using quality-adjusted survival time without symptoms or toxicity (Q-TWiST) methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!